Waselius & Wist advised Chr. Hansen in an acquisition from Valio Oy of a business that includes the LGG® trademarks and strain and related customer agreements, a collection of 3,200 strains and a production site in Tikkurila, Finland, which currently produces the LGG® strain and a number of specialty strains used in dairy production. LGG® is the best documented probiotic strain in the world that has been used in food and dietary supplements since 1990 and has a proven beneficial effect on the gastrointestinal and immune system.
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. Chr. Hansen has a total turnover of EUR 859 million (2014/15 financial year) and some 2.600 employees. Chr. Hansen is listed on Nasdaq Copenhagen.